Health Care • Biotechnology: Pharmaceutical Preparations
$593.54 ▲ +7.06
(+1.20%)
MKT CAP: $25.46B • VOL: 370.6K
52W L $430 52W H $610
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$499
MEDIAN
$665
MEAN
$677
HIGH
$807
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE UTHR TAPE
UTHR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $718.18 | $682.57 | 2025-02-14 | $540.12 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $747.86 | $700.38 | 2025-02-06 | $557.93 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $676.64 | $652.89 | 2025-01-29 | $569.80 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $605.41 | — | 2025-01-17 | $581.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $522.32 | $563.86 | 2025-01-09 | $528.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $706.31 | $617.28 | 2024-12-18 | $516.38 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $575.73 | $599.48 | 2024-12-04 | $551.99 | -4.3% | 48% | C |